Literature DB >> 679182

Deoxycytidine kinase and cytosine nucleoside deaminase activities in synchronized cultures of normal rat kidney cells.

C W Wan, T W Mak.   

Abstract

Previous work has suggested that 1-beta-D-arabinofuranosylcytosine 5'-triphosphate is the active metabolite of 1-beta-D-arabinofuranosylcytosine. The amount of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate formed in tissues has been shown to be influenced by the relative levels of deoxycytidine kinase and cytosine deaminase. In this study we have measured the intracellular levels of deoxycytidine kinase and cytosine deaminase activities in synchronized cultures of normal rat kidney cells. The deoxycytidine kinase activity was found to be cell cycle related with a minor peak of activity in early G1 phase and a major peak of activity in middle and late S phase. The cytosine deaminase activity was also found to be cycle dependent with a peak of activity at G1 phase and another at S phase of the cell cycle. Similar results were obtained when cytosine deaminase activities were measured with cytidine, deoxycytidine, or 1-beta-D-arabinofuranosylcytosine as substrate. Present studies also confirmed earlier studies by other workers that the main effect of 1-beta-D-arabinofuranosylcytosine is in the late S phase of the cell cycle.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 679182

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  5 in total

Review 1.  Cytosine arabinoside in the treatment of acute myeloid leukemia: the role and place of high-dose regimens.

Authors:  W Hiddemann
Journal:  Ann Hematol       Date:  1991-04       Impact factor: 3.673

2.  CNT1 expression influences proliferation and chemosensitivity in drug-resistant pancreatic cancer cells.

Authors:  Yangzom D Bhutia; Sau Wai Hung; Bhavi Patel; Dylan Lovin; Rajgopal Govindarajan
Journal:  Cancer Res       Date:  2011-02-22       Impact factor: 12.701

Review 3.  High-dose cytosine arabinoside: pharmacological and clinical aspects.

Authors:  W G Peters; L P Colly; R Willemze
Journal:  Blut       Date:  1988-01

4.  Cell cycle-specific metabolism of arabinosyl nucleosides in K562 human leukemia cells.

Authors:  V Gandhi; W Plunkett
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

5.  Overcoming S-phase checkpoint-mediated resistance: sequence-dependent synergy of gemcitabine and 7-ethyl-10-hydroxycamptothecin (SN-38) in human carcinoma cell lines.

Authors:  Marina Gálvez-Peralta; Nga T Dai; David A Loegering; Karen S Flatten; Stephanie L Safgren; Jill M Wagner; Matthew M Ames; Larry M Karnitz; Scott H Kaufmann
Journal:  Mol Pharmacol       Date:  2008-05-28       Impact factor: 4.436

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.